Pipeline

Passion for Discovery

pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.


CANDIDATE

Drug Discovery
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

APPROVED
R/R AML
 
 
Phase 3 IDHENTIFY Ongoing
 
U.S.
IC-Eligible Frontline AML
 
Phase 1b Combo Ongoing
IC-Ineligible Frontline AML
 
Phase 1/2 Combo Ongoing
  • Celgene has worldwide development and commercialization rights.Agios has U.S. co –promotion and royalty rights.
R/R AML
 
Phase 1 Dose-Escalation & Expansion Ongoing
 
U.S.
IC-Eligible Frontline AML
 
Phase 1b Combo Ongoing
IC-Ineligible Frontline AML
 
Phase 1/2 Combo Ongoing
Phase 3 AGILE Ongoing
Cholangio
 
 
Phase 3 ClarlDHy Ongoing
Glioma
 
Perioperative Study Ongoing
Glioma
 
Perioperative Study Ongoing

Joint worldwide collaboration with Celgene.   

PK Deficiency
 
Phase 2 DRIVE PK Ongoing
PK Deficiency
ACTIVATE-T Ongoing
MTAP-Deleted Tumors
 
Phase 1 Dose-Escalation Ongoing